MedTrace Logo

Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional Biomarkers

NCT02362789 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 132

Last updated 2018-12-28

Study results available
· View outcomes & findings →

Summary

The study is designed to explore the kinetics of psoriasis symptoms, pruritus intensity and lesional biomarkers.

Conditions

Interventions

BIOLOGICAL

Secukinumab

150 mg secukinumab in 1 ml solution for subcutaneous injection (pre-filled syringe)

BIOLOGICAL

Placebo

Matching placebo in 1 ml solution for subcutaneous injection (pre-filled syringe)

Sponsors & Collaborators

Principal Investigators

  • Study Lead · Muenster

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-04
Primary Completion
2016-07-15
Completion
2016-07-15

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02362789 on ClinicalTrials.gov